Solventum (SOLV) Q2 2024 earnings summary

Executive summary

• Completed spin-off from 3M on April 1, 2024, becoming an independent public company listed on the NYSE, with business continuity maintained post-separation.

• Q2 2024 net sales were $2.081 billion, up 0.2% reported and 1.3% organic year-over-year, aided by backorder improvements and normalized pricing.

• Adjusted EPS was $1.56, including a full quarter of interest expense; GAAP EPS was $0.51.

• Operating income for Q2 2024 was $244 million (GAAP) and $430 million (adjusted), with margins pressured by higher standalone costs and interest expense.

• Raised full-year 2024 guidance for organic sales growth and adjusted EPS, reflecting improved business continuity and strategic execution.

Financial highlights

• Q2 2024 net sales: $2.081 billion (+0.2% reported, +1.3% organic); adjusted operating margin: 20.7%; GAAP operating margin: 11.7%.

• Adjusted EPS: $1.56; GAAP EPS: $0.51; net income: $89 million, down from $321 million in Q2 2023.

• Gross margin: 55.8% (adjusted), 54.6% (GAAP), both down year-over-year due to higher costs and unfavorable mix.

• Free cash flow for Q2 was $297 million; cash from operations was $355 million.

• Interest expense for Q2 2024 was $114 million, reflecting new capital structure.

Outlook and guidance

• Full-year 2024 organic sales growth guidance raised to 0%–1%; adjusted EPS guidance increased to $6.30–$6.50.

• Free cash flow guidance maintained at $700–$800 million.

• Adjusted effective tax rate now expected at 18%–19% for 2024.

• 3M supply agreement mark-up to impact income statement starting Q3 2024.

• SKU rationalization project underway, not expected to materially impact 2024 revenue or margin.